Hansa Biopharma announces positive reimbursement decision for Idefirix® (imlifidase) in the Czech Republic
Idefirix® is the first and only product approved for use in highly sensitized patients waiting for a kidney transplant in the Czech Republic1,2 Availability of Idefirix® for eligible highly sensitized patients to begin January 1, 2023 LUND, Sweden, Jan. 2 …